Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

474 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy of pembrolizumab in microsatellite-stable, tumor mutational burden-high metastatic colorectal cancer: genomic signatures and clinical outcomes.
Yamaguchi K, Tsuchihashi K, Ueno S, Uehara K, Taguchi R, Ito M, Isobe T, Imajima T, Kitazono T, Tanoue K, Ohmura H, Akashi K, Baba E. Yamaguchi K, et al. Among authors: baba e. ESMO Open. 2025 Jan 6;10(1):104108. doi: 10.1016/j.esmoop.2024.104108. Online ahead of print. ESMO Open. 2025. PMID: 39765187 Free article.
Lymphoproliferative Disorder in an Esophageal Cancer Patient Treated with Pembrolizumab.
Matsumura T, Tsuchihashi K, Yamamoto T, Jinnouchi F, Kusano W, Kusumoto Y, Arimizu K, Ohmura H, Kuma Y, Moriyama S, Yamaguchi K, Ito M, Isobe T, Ariyama H, Oda Y, Akashi K, Baba E. Matsumura T, et al. Among authors: baba e. Intern Med. 2024 Oct 18. doi: 10.2169/internalmedicine.3743-24. Online ahead of print. Intern Med. 2024. PMID: 39428537 Free article.
Spatial dynamics of CD39+CD8+ exhausted T cell reveal tertiary lymphoid structures-mediated response to PD-1 blockade in esophageal cancer.
Tanoue K, Ohmura H, Uehara K, Ito M, Yamaguchi K, Tsuchihashi K, Shinohara Y, Lu P, Tamura S, Shimokawa H, Isobe T, Ariyama H, Shibata Y, Tanaka R, Kusaba H, Esaki T, Mitsugi K, Kiyozawa D, Iwasaki T, Yamamoto H, Oda Y, Akashi K, Baba E. Tanoue K, et al. Among authors: baba e. Nat Commun. 2024 Oct 19;15(1):9033. doi: 10.1038/s41467-024-53262-w. Nat Commun. 2024. PMID: 39426955 Free PMC article.
Safety and immunogenicity of a modified mRNA-lipid nanoparticle vaccine candidate against COVID-19: Results from a phase 1, dose-escalation study.
Essink BJ, Shapiro C, Isidro MGD, Bradley P, Pragalos A, Bloch M, Santiaguel J, Frias MV, Miyakis S, Alves de Mesquita M, Berrè S, Servais C, Waugh N, Hoffmann C, Baba E, Schönborn-Kellenberger O, Wolz OO, Koch SD, Ganyani T, Boutet P, Mann P, Mueller SO, Ramanathan R, Gaudinski MR, Vanhoutte N. Essink BJ, et al. Among authors: baba e. Hum Vaccin Immunother. 2024 Dec 31;20(1):2408863. doi: 10.1080/21645515.2024.2408863. Epub 2024 Oct 18. Hum Vaccin Immunother. 2024. PMID: 39422261 Free PMC article. Clinical Trial.
Phase II Trial of Adjuvant S-1 Following Neoadjuvant Chemotherapy and Surgery in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma: The PIECE Trial.
Nomura M, Yamaguchi T, Chin K, Hato S, Kato K, Baba E, Matsubara H, Mukaida H, Yoshii T, Tsuda M, Tsubosa Y, Kitagawa Y, Oze I, Ishikawa H, Muto M. Nomura M, et al. Among authors: baba e. Ann Surg Oncol. 2025 Jan;32(1):302-311. doi: 10.1245/s10434-024-16325-2. Epub 2024 Oct 7. Ann Surg Oncol. 2025. PMID: 39375260 Free PMC article. Clinical Trial.
474 results